Clinical trials: Newly Diagnosed
AML
Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML
The goal of this Phase IB study is to evaluate the safety and tolerability of APVO436 in naïve elderly unfit patients with newly diagnosed primary AML at the RP2D level when it is used as an adjunct to the standard of care and…
- Trial name
- NCT04973618
- Testing
- APVO436
- Sponsor
- Aptevo Therapeutics
FLT3-mutated Acute Myeloid Leukemia
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
This study will evaluate the safety, efficacy and pharmacokinetics of midostaurin in combination with standard chemotherapy in pediatrics patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia.
- Trial name
- NCT03591510
- Testing
- Midostaurin, Fludarabine, Cytarabine
- Where
- 15 sites in Czechia, Germany and 8 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia (AML)
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.
- Trial name
- NCT06634394
- Testing
- APVO436, Venetoclax, Azacitidine
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- Aptevo Therapeutics
Newly Diagnosed Multiple Myeloma
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma
The goal of this clinical study iMMagine-4 is to compare and assess the safety and effectiveness of anitocabtagene autoleucel versus standard of care therapy (SOCT) in participants with newly diagnosed multiple myeloma (NDMM) who…
- Trial name
- iMMagine-4 (NCT07887672)
- Testing
- Anitocabtagene autoleucel, Daratumumab, Bortezomib
- Volunteers
- 600 people
- Sponsor
- Kite, A Gilead Company
Hypertension
Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine
PRECIOUS Study aims to evaluate the efficacy and safety of therapy with fixed-dose combination (FDC) of perindopril/amlodipine (Amlessa®) and FDC of perindopril/indapamide/amlodipine (Co-Amlessa®) on blood pressure reduction in…
- Trial name
- PRECIOUS (NCT03738761)
- Testing
- Amlessa®, Co-Amlessa®
- Where
- 34 sites in Armenia, Croatia and 5 more
- Volunteers
- 471 people
- Sponsor
- KRKA
Type 1 Diabetes Mellitus
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)
This is a randomized, parallel group, double-blind Phase 2 study with a blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on…
- Trial name
- FABULINUS (NCT06111586)
- Testing
- Frexalimab, Insulin
- Where
- 79 sites in United States, Austria and 14 more
- Volunteers
- 197 people
- Sponsor
- Sanofi
Glioblastoma Multiforme (GBM)
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
This study was designed to evaluate the safety, tolerability, efficacy and pharmacokinetics of JK-1201I combined with adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and concomitant…
- Trial name
- NCT06595186
- Testing
- JK-1201I, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- JenKem Technology Co., Ltd.
Primary Peritoneal Carcinoma, Tumor
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
This is an open-label, two-arm, multicenter feasibility study to evaluate the safety and tolerability of pazopanib in combination with carboplatin and paclitaxel in female subjects with newly diagnosed advanced gynaecological…
- Conditions
- Primary Peritoneal Carcinoma, Tumor, Epithelial Ovarian Cancer, Uterine Disease
- Trial name
- NCT00561795
- Testing
- pazopanib (GW786034), carboplatin, paclitaxel
- Where
- 5 sites in France, Germany
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Chronic Myeloid Leukemia (CML)
Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
A non-randomized, open-label study to investigate the effects of imatinib mesylate on the pharmacokinetics of acetaminophen/paracetamol in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic…
- Trial name
- NCT00428909
- Testing
- Imatinib/Acetaminophen
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Newly Diagnosed Multiple Myeloma
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
The goal of this clinical study iMMagine-6 is to compare and assess the safety and effectiveness of anitocabtagene autoleucel versus autologous stem cell transplant in participants with newly diagnosed multiple myeloma (NDMM).
- Trial name
- iMMagine-6 (NCT07903506)
- Testing
- Anitocabtagene Autoleucel, Isatuximab, Bortezomib
- Volunteers
- 750 people
- Sponsor
- Kite, A Gilead Company
Acute Myeloid Leukemia
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
A global, multicenter, randomized, double-blind, placebo-controlled, phase III pivotal registration study, to evaluate the efficacy of APG-2575 (Lisaftoclax) combined with azacitidine (AZA) versus placebo combined with…
- Trial name
- NCT06389292
- Testing
- APG-2575(Lisaftoclax ), Azacitidine Injection
- Where
- 6 sites in China, Russia
- Volunteers
- 486 people
- Sponsor
- Ascentage Pharma Group Inc.
Glioblastoma
TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)
This prospective multicenter non-interventional study (NIS) aims at confirming the survival benefit of Optune Gio® - in terms of OS and PFS - and describing device usage (compliance will be measured through patient's usage…
- Trial name
- TIGER France (NCT06924099)
- Where
- 24 sites in France
- Volunteers
- 430 people
- Sponsor
- NovoCure Ltd.
Prostate Cancer
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk…
- Trial name
- MIRROR (NCT06074510)
- Testing
- Piflufolastat F 18 Intravenous Solution [PYLARIFY]
- Where
- 14 sites in United States
- Volunteers
- 274 people
- Sponsor
- Lantheus Medical Imaging
Gaucher Disease, Type 1
Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular…
- Trial name
- NCT00954460
- Testing
- velaglucerase alfa
- Where
- 32 sites in United States
- Sponsor
- Shire
Leukemia, Myeloid
Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)
Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar may help daunorubicin and cytarabine kill more cancer cells by making cancer cells more sensitive to the drugs.
- Trial name
- NCT00129168
- Testing
- Zosuquidar, Daunorubicin, Cytarabine
- Volunteers
- 100 people
- Sponsor
- Kanisa Pharmaceuticals
Glioblastoma
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
The primary objective of this study is to assess the safety and tolerability, feasibility and biological activity (immunogenicity) of the actively personalized vaccination (APVAC) concept in newly diagnosed glioblastoma (GB)…
- Trial name
- NCT02149225
- Testing
- APVAC1 vaccine plus Poly-ICLC and GM-CSF, APVAC2 vaccine plus Poly-ICLC and GM-CSF
- Where
- 6 sites in Denmark, Germany and 3 more
- Volunteers
- 16 people
- Sponsor
- Immatics Biotechnologies GmbH
Renal Cell Carcinoma
Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer
The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of multiple administrations of dendritic cell Immunotherapeutic to patients with newly diagnosed with…
- Trial name
- NCT00272649
- Testing
- AGS-003
- Where
- 10 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- Argos Therapeutics
Lymphoma, T-Cell, Peripheral
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Study of ONTAK and CHOP (chemotherapy drugs) to find out their ability to make Peripheral T-cell lymphoma disappear (for any period of time) and potentially lengthen life.
- Trial name
- NCT00211185
- Testing
- Denileukin diftitox, Cyclophosphamide, Doxorubicin
- Where
- 49 sites in United States
- Volunteers
- 49 people
- Sponsor
- Eisai Inc.
Diabetes Mellitus, Type 2
Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea
The purpose of this study is investigating the clinical characteristics of newly diagnosed, drug naïve type 2 diabetic patients according to insulin secretion and insulin resistance.
- Trial name
- SURPRISE (NCT01154244)
- Testing
- HOMA-IR
- Where
- 2 sites in South Korea
- Volunteers
- 1,439 people
- Sponsor
- GlaxoSmithKline
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- OVATION 2 (NCT03393884)
- Testing
- IMNN-001, Carboplatin, Paclitaxel
- Where
- 21 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Imunon